BUPRENORPHINE vs. METADONE IN THE TREATMENT OF OPIOID USE DISORDER DURING PREGNANCY
DOI:
https://doi.org/10.47820/recima21.v5i1.4741Keywords:
Neonatal abstinence syndrome. Pregnancy. Drug treatment.Abstract
Introduction: Opioid withdrawal is an important clinical syndrome that can cause considerable discomfort. Although considered non-life-threatening, the clinical manifestations of opioid withdrawal can lead to severe fluid loss and electrolyte abnormalities that result in hemodynamic instability and death. Objectives: to evaluate the efficacy and safety of buprenorphine and methadone in the treatment of opioid use disorder in pregnant women and to analyze which medication is superior. Materials and methods: This is an integrative review, in which the guiding question was “Is buprenorphine superior to methadone in the treatment of opioid use disorder in pregnant women?” The search for articles took place in PubMed using the terms “buprenorphine”, “methadone”, “treatment”, “opioid use disorder” and “pregnancy”, combined using Boolean operators. Results and discussion: Opioid use during pregnancy is associated with a number of adverse pregnancy outcomes, including maternal death at birth, intrauterine growth restriction, placental abruption, preterm labor, oligohydramnios, stillbirth, premature rupture of membranes and cesarean delivery when compared with no opioids. Compared to babies exposed to buprenorphine, babies exposed to methadone had a statistically significant increased risk of neonatal abstinence syndrome. Conclusion: Based on our research, buprenorphine and methadone are equally effective and safe in the treatment of opioid use disorder, however, buprenorphine has been shown to be safer for newborns in relation to neonatal abstinence syndrome.
Downloads
References
Srivastava A Benjamin, Mariani John J, Levin Frances R. New directions in the treatment of opioid withdrawal. The Lancet. 2020;395(10241):1938-1948.
Dydyk Alexander M, Jain Nitesh K, Gupta Mohit. Opioid use disorder. In: StatPearls [Internet]. StatPearls Publishing; 2022.
Ober Allison J, et al. Patient predictors of substance use disorder treatment initiation in primary care. Journal of substance abuse treatment. 2018;90:64-72.
Galanter Marc. Combining medically assisted treatment and Twelve-Step programming: a perspective and review. The American Journal Of Drug And Alcohol Abuse. 2018;44(2):151-159.
Jones Hendrée E, Kraft Walter K. Analgesia, opioids, and other drug use during pregnancy and neonatal abstinence syndrome. Clinics in Perinatology. 2019;46(2):349-366.
Rodriguez Christina E, Klie Kaylin A. Pharmacological treatment of opioid use disorder in pregnancy. In: Seminars in perinatology. WB Saunders; 2019. p. 141-148.
Ercole Flávia Falci, Melo Laís Samara de, Alcoforado Carla Lúcia Goulart Constant. Revisão integrativa versus revisão sistemática. Reme: Revista Mineira de Enfermagem. 2014;18(1):09-11.
Mendes Karina Dal Sasso, Silveira Renata Cristina de Campos Pereira, Galvão Cristina Maria. Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto & contexto-enfermagem. 2008;17:758-764.
De Sousa Luís Manuel Mota et al. A metodologia de revisão integrativa da literatura em enfermagem. Revista investigação em enfermagem. 2017;21(2):17-26.
Patrick Stephen W. et al. Association of pregnancy and insurance status with treatment access for opioid use disorder. JAMA network open. 2020;3(8):e2013456-e2013456.
Tobon Amalia Londono, Habecker Erin, Forray Ariadna. Opioid use in pregnancy. Current Psychiatry Reports. 2019;21:1-10.
Krans Elizabeth E, et al. Medication-assisted treatment utilization among pregnant women with opioid use disorder. Obstetrics and gynecology. 2019;133(5):943.
Suarez Elizabeth A. et al. Buprenorphine versus methadone for opioid use disorder in pregnancy. New England Journal of Medicine. 2022;387(22):2033-2044..
Harter Kristin. Opioid use disorder in pregnancy. Mental Health Clinician. 2019;9(6):359-372.
Sujan Ayesha et al. A retrospective, observational study on medication for opioid use disorder during pregnancy and risk for neonatal abstinence syndrome. Family practice. 2022;39(2):11-315.
Tran Emmy L, et al. The MATernaL and Infant NetworK to understand outcomes associated with treatment of opioid use disorder during pregnancy (MAT-LINK): surveillance opportunity. Journal of Women's Health. 202029(12):1491-1499.
Wang, Shuang et al. Comparative Safety Analysis of Opioid Agonist Treatment in Pregnant Women with Opioid Use Disorder: A Population-Based Study. Drug Safety. 2023;46(3):257-271.
Downloads
Published
License
Copyright (c) 2024 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
This work is licensed under a Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
